This study tests if the drug riluzole can help cancer survivors with brain issues called cognitive impairment. Cognitive impairment means having trouble with memory or thinking after cancer treatments. This study is phase 2a, which means it is in an early stage of testing the drug's effects. It's randomized and double-blinded, meaning that neither the participants nor the researchers know who is getting the actual drug or a placebo (a fake treatment). The study checks how riluzole changes BDNF levels, a factor in the blood linked to brain health.
- The study is for cancer survivors who finished treatment or had brain radiation.
- Participants must be 18 or older and able to complete questionnaires.
- Women who are pregnant or breastfeeding cannot join.
If you join, you'll need to complete tests and assessments. It's important to note the risks if you're taking other medications. Always talk to your doctor to see if this study is right for you.
How understandable was the trial content above?
Hard to understand
Easy to understand